MDACC Study No:2010-0244 ( NCT No: NCT01204164)
Title: A Phase 1 Dose - Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies
Principal Investigator:Elias Jabbour
Treatment Agent:TG02
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
and schedule of TG02 citrate that can be given to patients with certain types
of leukemia, MDS, and CML. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloma
Phase of Study:Phase I
Treatment Agents:TG02
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Tragara Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults